Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Veliparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 known ✓ | P09874 | 20/20 | 1.00 |
| ▸ | PARP2 known ✓ | Q9UGN5 | 6/20 | 1.00 |
| ▸ | PARP3 known ✓ | Q9Y6F1 | 1/20 | 0.98 |
| ▸ | TNKS | O95271 | 1/20 | 0.98 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.98 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.98 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.98 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.98 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Veliparib SCHEMBL2368887 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL2368889 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29455770 | 1.00 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422320 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422319 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29354914 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL5511373 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL422318 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL30418660 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 | |
| Veliparib SCHEMBL29843298 | 0.99 | PARP1 (1.00) | PARP1PARP2TNKSPARP14PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180195046-A1 | INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHOD OF MAKING AND USING | PEKING UNIVERSITY (CN) | 2018-07-12 | — | — | US | claimed |
| EP-4731270-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | The Regents of The University of California (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | AGENDIA N V (NL) | 2026-04-23 | — | — | US | disclosed |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | AGENDIA, INC. | 2026-02-19 | — | — | US | disclosed |
| EP-4526470-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | Agendia N.V. (NL) | 2025-03-26 | — | — | EP | disclosed |
| EP-4526471-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | Agendia N.V. (NL) | 2025-03-26 | — | — | EP | disclosed |
| EP-4482986-A1 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-01 | — | — | EP | disclosed |
| WO-2024263637-A1 | COMBINATION THERAPY WITH PEPTIDE RECEPTOR RADIONUCLIDE AND DNA REPAIR INHIBITOR | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-3334820-B1 | INDUCED EXTENDED PLURIPOTENT STEM CELLS, METHODS OF MAKING AND USING | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RES INSTITUTE CO LTD (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20240060138-A1 | BREAST CANCER-RESPONSE PREDICTION SUBTYPES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-02-22 | — | — | US | disclosed |
| EP-2722046-A1 | 2-((R)-2-methylpyrrolidin-2-YL)-1H-benzimidazole-4-carboxamide crystalline form 1 | AbbVie Bahamas Ltd. (BS) | 2014-04-23 | — | — | EP | disclosed |
| US-20130123317-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBVIE INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8372987-B2 | Title compound is Veliparib, a Poly(ADP-ribose) polymerase i.e. PARP inhibitor; anticancer agent | ABBVIE INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8013168-B2 | Veliparib crystal structure; an anticancer PARP inhibitor | ABBOTT LABORATORIES (US) | 2011-09-06 | — | — | US | disclosed |
| EP-2217603-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | Abbott Laboratories (US) | 2010-08-18 | — | — | EP | disclosed |
| EP-2212327-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | Abbott Laboratories (US) | 2010-08-04 | — | — | EP | disclosed |
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | disclosed |
| US-20090099246-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2009049109-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 2 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049111-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | ABBOTT LABORATORIES (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099245-A1 | 2-{(R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, MALT1, GOT2 | PARP1 739/4885PARP2 266/4885PARP3 1454/4885 |
| US-20260110035-A1 | DNA REPAIR SIGNATURE AND PREDICTION OF RESPONSE FOLLOWING CANCER THERAPY | BRCA1, PARP3, PARP2 | PARP1 4/4885PARP2 3/4885PARP3 2/4885 |
| US-20130123317-A1 | 2-((R)-2-METHYLPYRROLIDIN-2-YL)-1H-BENZIMIDAZOLE-4-CARBOXAMIDE CRYSTALLINE FORM 1 | TPMT, UACA, GOT2 | PARP1 757/4885PARP2 260/4885PARP3 1419/4885 |
| US-20260049359-A1 | PREDICTION OF RESPONSE TO IMMUNE THERAPY IN BREAST CANCER PATIENTS | BRCA1, PDCD1, CD274 | PARP1 1484/4885PARP2 498/4885PARP3 243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.